US 12,186,309 B2
RNA virus inhibitor compounds and uses thereof
James A. Nieman, Sherwood Park (CA); M. Joanne Lemieux, Edmonton (CA); D. Lorne Tyrrell, Edmonton (CA); Mostofa Hena, Edmonton (CA); Appan Srinivas Kandadai, Edmonton (CA); Alexandr Belovodskiy, Edmonton (CA); Michael A. Joyce, Edmonton (CA); and Elena Arutyunova, Edmonton (CA)
Assigned to The Governors of the University of Alberta, Edmonton (CA)
Filed by The Governors of the University of Alberta, Edmonton (CA)
Filed on Sep. 22, 2022, as Appl. No. 17/950,785.
Claims priority of provisional application 63/350,542, filed on Jun. 9, 2022.
Claims priority of provisional application 63/248,916, filed on Sep. 27, 2021.
Prior Publication US 2023/0108588 A1, Apr. 6, 2023
Int. Cl. A61K 31/454 (2006.01); A61P 31/14 (2006.01)
CPC A61K 31/454 (2013.01) [A61P 31/14 (2018.01)] 24 Claims
OG exemplary drawing
 
1. A compound of formula II:

OG Complex Work Unit Chemistry
wherein:
R6 is selected from —CH3 and —CHF2;
each R7 is independently selected from —H, -D and —CH3, or together two R7 and the carbon they are attached to form a cyclopropyl group; and
Z is selected from —CH2CH2CH2— and —C(CH3)2—;
or a pharmaceutically acceptable salt, solvate, or hydrate thereof.